NASDAQ:CAMP - Nasdaq - US13463J1016
Data from Single Ascending Dose (SAD) portion of Phase 1 study of CMP-CPS-001 for the treatment of urea cycle disorders (UCDs) demonstrates favorable...
Industry veterans John Maraganore, Ph.D., and Rachel Meyers, Ph.D., to provide strategic guidance on the company’s RNA Actuating platform to develop a new class of RNA medicines that upregulate protein coding genes
CAMBRIDGE, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company...
- Completed Initial Public Offering (IPO) of common stock, raising gross proceeds of $82.1M- Single Ascending Dose (SAD) portion of Phase 1 study of...
CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company...
Pre-market stock movers are worth checking out on Friday as we dig into all of the biggest news affecting shares this morning!
It's time to start Tuesday with a breakdown of the biggest pre-market stock movers traders will want to know about this morning!
CALAMP REACHES COMPREHENSIVE AGREEMENT TO SIGNIFICANTLY REDUCE DEBT, GO PRIVATE, AND STRENGTHEN FINANCIAL FLEXIBILITY...
CalAmp Corp., which develops business software designed to track vehicles and improve company logistics, has filed bankruptcy to complete a lender-backed plan to cut debt.
CalAmp Enhances School Bus Solutions Suite with Dispatch Monitor...